Recent blog posts
"First-in-class" CD3/CD2/CD19 Tri-specific Antibody Drug Receives IND Approval in China
Hot Spotlight
4 min read
"First-in-class" CD3/CD2/CD19 Tri-specific Antibody Drug Receives IND Approval in China
6 November 2024
Recently,the Center for Drug Evaluation of the NMPA announced the acceptance of the investigational new drug (IND) application for Novartis's PIT565 injection.
Read →
A New Combo for Synergistically Improving Liver Homeostasis! Promising Benefits for Obesity and Metabolic Complications Treatment
Hot Spotlight
4 min read
A New Combo for Synergistically Improving Liver Homeostasis! Promising Benefits for Obesity and Metabolic Complications Treatment
6 November 2024
Tiziana Life Sciences announced that its intranasally administered anti-CD3 monoclonal antibody, foralumab.
Read →
Simcere obtained rights to the first-in-class QPCT inhibitor, with new Phase 2 data announced
Hot Spotlight
4 min read
Simcere obtained rights to the first-in-class QPCT inhibitor, with new Phase 2 data announced
6 November 2024
Recently, Vivoryon Therapeutics presented new analysis data for varoglutamstat at the 2024 American Society of Nephrology (ASN) meeting.
Read →
Biogen and Neomorph Collaborate on Developing Multiple Molecular Glue Degraders
Hot Spotlight
4 min read
Biogen and Neomorph Collaborate on Developing Multiple Molecular Glue Degraders
6 November 2024
Novartis will acquire a clinical-stage molecular glue named MRT-6160, providing Monte Rosa with an upfront payment of $150 million.
Read →
miRNA Therapeutics: Cutting-Edge Advances from Mechanism Exploration to Clinical Applications and Market Outlook
Hot Spotlight
9 min read
miRNA Therapeutics: Cutting-Edge Advances from Mechanism Exploration to Clinical Applications and Market Outlook
31 October 2024
According to statistical data, the miRNA drug market was estimated at approximately $160.5 million in 2017, with an expected compound annual growth rate (CAGR) of 18.6%.
Read →
Exploring Growth and Innovation within the Global Antisense Oligonucleotide Therapeutics Market
Hot Spotlight
10 min read
Exploring Growth and Innovation within the Global Antisense Oligonucleotide Therapeutics Market
29 October 2024
As a cutting-edge therapeutic approach, antisense oligonucleotide drugs precisely target the mRNA or pre-mRNA of disease-causing genes.
Read →
Targeting the Source of IgA Nephropathy: World’s First APRIL Antibody Shows Positive Phase III Results
Hot Spotlight
5 min read
Targeting the Source of IgA Nephropathy: World’s First APRIL Antibody Shows Positive Phase III Results
29 October 2024
Otsuka Pharmaceutical announced positive top-line interim data from the phase III clinical trial of sibeprenlimab for treating adults with IgA nephropathy.
Read →
Hope Medicine's "World's First" PRLR Monoclonal Antibody Announces Latest Phase 2 Clinical Progress
Hot Spotlight
4 min read
Hope Medicine's "World's First" PRLR Monoclonal Antibody Announces Latest Phase 2 Clinical Progress
29 October 2024
Hope Medicine (HopeMed) announced positive interim results from a Phase 2 study of HMI-115 in women with moderate to severe endometriosis-associated pain.
Read →
Tonix Pharmaceuticals Submits NDA for TNX-102 SL, Offering New Hope for Fibromyalgia Patients
Hot Spotlight
3 min read
Tonix Pharmaceuticals Submits NDA for TNX-102 SL, Offering New Hope for Fibromyalgia Patients
29 October 2024
Tonix Pharmaceuticals announced that it has submitted a New Drug Application (NDA) to the U.S. FDA for TNX-102 SL (Cyclobenzaprine hydrochloride).
Read →
A New Medication for Epileptic Encephalopathy Initiates Phase 3 Clinical Trials
Hot Spotlight
3 min read
A New Medication for Epileptic Encephalopathy Initiates Phase 3 Clinical Trials
29 October 2024
Longboard Pharmaceuticals has recently announced the initiation of the global Phase 3 DEEp SEA study.
Read →
Novo Nordisk Completes Phase 2a Clinical Study of New Weight Loss Product
Hot Spotlight
4 min read
Novo Nordisk Completes Phase 2a Clinical Study of New Weight Loss Product
29 October 2024
Novo Nordisk announced on its official website the primary results of a Phase 2a clinical trial for its investigational drug monlunabant (previously known as INV-202).
Read →
Sanofi Joins Forces with RadioMedix and Orano Med to Pioneer Radioligand Therapies for Rare Cancers
Hot Spotlight
4 min read
Sanofi Joins Forces with RadioMedix and Orano Med to Pioneer Radioligand Therapies for Rare Cancers
29 October 2024
Sanofi announced its entry into the nuclear medicine field through an exclusive licensing agreement with RadioMedix and Orano Med to jointly develop next-generation RLT for rare cancers.
Read →